Keyword

molecular response

Description: Changes in molecular activity, expression, or composition that occur in response to environmental conditions, stress, or treatment in biological systems.

Primary topic: Chronic Myeloid Leukemia Treatments (49%)

OpenAlex ID: keywords/molecular-response

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

2013 · Michele Baccarani, Michael W. Deininger, et al. · Blood · 1,987

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

2006 · M. Baccarani · Blood · 1,278

PDF

Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia

2003 · Tim P. Hughes, Jaspal Kaeda, et al. · New England Journal of Medicine · 1,218

PDF

Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

2010 · David Marin, Alexandra Bazeos, et al. · Journal of Clinical Oncology · 909

PDF

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

2016 · A Hochhaus, G Saglio, et al. · Leukemia · 839

PDF

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

2012 · Jorge E. Cortes, Hagop Kantarjian, et al. · New England Journal of Medicine · 773

International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.

2009 · Michael Deininger, Stephen G O'Brien, et al. · Blood · 616

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

2006 · Andreas Hochhaus, Hagop M. Kantarjian, et al. · Blood · 609

PDF

Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas

2020 · Qing Deng, Guangchun Han, et al. · Nature Medicine · 594

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

2008 · Jean-Jacques Kiladjian, Bruno Cassinat, et al. · Blood · 583

PDF

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation

2001 · P. Colombat · Blood · 524

Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies

2012 · Nicola Gökbuget, Michael Kneba, et al. · Blood · 493

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

2011 · Jorge E. Cortes, Hagop M. Kantarjian, et al. · Blood · 463

OCT-1–mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

2006 · Deborah L. White, Verity A. Saunders, et al. · Blood · 435

Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera

2009 · Alfonso Quintás-Cardama, Hagop Kantarjian, et al. · Journal of Clinical Oncology · 428

PDF

Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia

2010 · Claude Preudhomme, Joëlle Guilhot, et al. · New England Journal of Medicine · 392

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials

2008 · Susan Branford, Linda Fletcher, et al. · Blood · 388

Standardized definitions of molecular response in chronic myeloid leukemia

2012 · N C P Cross, H E White, et al. · Leukemia · 378

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

2021 · Hagop M. Kantarjian, Timothy P. Hughes, et al. · Leukemia · 350

PDF

Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade

2020 · Qu Zhang, Jia Luo, et al. · Cancer Discovery · 347

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

2017 · for the SAKK and the German CML Study Group, R Hehlmann, et al. · Leukemia · 341

PDF

Toxicity and Efficacy of Defined Doses of CD4+ Donor Lymphocytes for Treatment of Relapse After Allogeneic Bone Marrow Transplant

1998 · Edwin P. Alyea, Robert J. Soiffer, et al. · Blood · 318

Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer

2019 · Bradon R. McDonald, Tania Contente-Cuomo, et al. · Science Translational Medicine · 306

PDF

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

2017 · A Hochhaus, T Masszi, et al. · Leukemia · 293

PDF

Discontinuation of imatinib therapy after achieving a molecular response

2004 · Jorge Cortes, Susan O'Brien, et al. · Blood · 280

PDF

Works count: 3,800

Citation count: 44,490